RxDoctor Payments Data

Emerentia Agyemang

Adult Health · Worcester, MANPI 1396155123

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Karyopharm Therapeutics Inc. accounts for 71.4% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for adult health clinicians in MA, where the typical reported total is $182.

$93in general payments, 2019–2025

Across 2 payments — averaging $46.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Karyopharm Therapeutics Inc.$67
  • Bristol Myers Squibb$27
$419,945in research payments, 2019–2025

Across 4 payments — averaging $104,986 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$420K

What the payments were for

  • Food & beverage$93100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$93 in reported general payments places this provider in the 30th percentile of 671 adult health providers in Massachusetts.

See all adult health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$57,408
Medicare patients
158
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide537$6,465,238
RevlimidLenalidomide299$5,169,614
PomalystPomalidomide201$4,103,458
VenclextaVenetoclax39$633,720
NinlaroIxazomib Citrate48$561,338
BrukinsaZanubrutinib18$180,569
EliquisApixaban69$54,494
XareltoRivaroxaban21$20,704
Acyclovir268$3,930
Atovaquone17$3,794
Omeprazole124$1,872
Fentanyl22$1,618
Colestipol Hcl26$1,366
Oxycodone Hcl78$1,162
Dexamethasone32$1,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$27$5,169,614299 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 671 adult health providers in Massachusetts.

Other adult health in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →